Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (3795)	2/10/1998 3:34:00 PM
From: Bhag Karamchandani	Read Replies (1) \| Respond to of 6136

Thanks for your valuable posts. I wholeheartedly agree with you (if this is what you meant) that the time has come for us to look at AGPH's prospects beyond Viracept, based on products in the pipeline. Mike Murphy ( CTSL) has an interesting approach to valuating Biotech Companies as a function of their R&D Investments, cash reserves and burn rates? I wonder if it could applied to AGPH. This thread has become, much too much, AIDS/ Viracept focussed. I understand the reasons why. And am not trying to downplay the importance of the discussions-But is there no news, from any quarter, regarding progress ( or lack thereof) by AGPH on other fronts?? For example: How does the experience of British Biotech in developing an antisense compound (?) for cancer treatment compare with AGPH, now that the former does not appear to have done as well as expected?? And is it true that AGPH total current short volume is approx. 13 times average daily volume. If so, can anyone estimate when the shorts are likely to cover and the impact of shorts covering on the stock price?? What is the latest on insider buying or selling??